Table 2.

Neoadjuvant androgen deprivation (AD) therapy and risk group classification

Neoadjuvant AD therapy	NCCN risk group classification
	Low	Intermediate	High	N/A	Total
	Number of patients (%)	Number of patients (%)	Number of patients (%)	Number of patients (%)	Total number of patients (%)
No	795 (58.0)	248 (48.1)	8 (36.4)	48 (66.7)	1099 (55.5)
Yes	576 (42.0)	268 (51.9)	14 (63.6)	24 (33.3)	882 (44.5)
Total with AD therapy information	1371	516	22	72	1981
N/A	114	66	19	57	256
Total	1485	582	41	129	2237

N/A, not available; NCCN, National Comprehensive Cancer Network.